From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Granix (tbo-filgrastim) is typically dosed at 5 mcg/kg body weight once daily as a subcutaneous injection for patients receiving myelosuppressive chemotherapy. Treatment should begin at least 24 hours after chemotherapy administration and continue daily until the expected neutrophil nadir has passed and neutrophil count has recovered to normal range, usually for up to 14 days per chemotherapy cycle. The medication comes in prefilled syringes of 300 mcg/0.5 mL and 480 mcg/0.8 mL. Patients or caregivers should be properly trained on administration technique, including proper disposal of needles. Common side effects include bone pain, which can be managed with non-narcotic analgesics. Granix works by stimulating the bone marrow to produce neutrophils, helping to reduce the risk of infection in patients whose neutrophil counts are decreased due to chemotherapy. Blood counts should be monitored regularly during therapy to assess response and determine when treatment can be discontinued.
According to the most recent study 1, tbo-filgrastim has demonstrated bioequivalence to reference filgrastim in terms of its pharmacokinetic and pharmacodynamic profiles, and has been shown to be effective in ameliorating severe neutropenia in patients receiving chemotherapy for various types of cancer. The study also notes that tbo-filgrastim is generally well tolerated, with a similar safety profile to that of reference filgrastim.
Key points to consider when prescribing Granix (tbo-filgrastim) include:
- Starting treatment at least 24 hours after chemotherapy administration
- Continuing treatment daily until the expected neutrophil nadir has passed and neutrophil count has recovered to normal range
- Monitoring blood counts regularly to assess response and determine when treatment can be discontinued
- Proper training on administration technique, including proper disposal of needles
- Management of common side effects, such as bone pain, with non-narcotic analgesics.
It's also important to note that the dosing and administration of Granix (tbo-filgrastim) may vary depending on the specific clinical context and patient population, and that the medication should be used in accordance with established guidelines and recommendations 2, 3, 4, 5.